Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05375825 | Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01913275 | Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy | withdrawn | N/A | 0 | All India Institute of Medical SciencesOTHER |
| 1 |
| Jan 31, 2024 |
| clinicaltrials |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05099536 | 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | withdrawn | Phase 2 | 0 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05331131 | Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial | withdrawn | Phase 2 | 0 | Northwell HealthOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04304079 | A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery | withdrawn | N/A | 0 | Chinese University of Hong KongOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05848843 | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03981718 | Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05315687 | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05035732 | A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study) | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT05724849 | Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | Vanderbilt University Medical CenterOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT00323180 | Investigation of Protein Biomarkers of Prostate Cancer | withdrawn | — | 0 | University of New MexicoOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT00323388 | Identification of Risk Allels for Prostate Cancer | withdrawn | — | 0 | University of New MexicoOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05153447 | A Multicomponent Technology Supported Care Delivery for Older Patients With Hematologic Malignancies (The M-Tech Study)(M-Tech) | withdrawn | N/A | 0 | Kah Poh LohOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04379830 | Preoperative Very Low Energy Diet for Obese Rectal Cancer Patients | withdrawn | N/A | 0 | McMaster UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03135652 | Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03193814 | Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer(XHZL) | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT06165809 | A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer | withdrawn | Phase 1 | 0 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT00979693 | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | withdrawn | Phase 2 | 0 | Multidisciplinary Association for Psychedelic StudiesOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | withdrawn | — | 0 | HKGepitherapeuticsINDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | withdrawn | Phase 2 | 0 | Advaxis, Inc.INDUSTRY | 0 | Dec 19, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT00250016 | Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) | withdrawn | — | 0 | University of New MexicoOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib(NSCLC) | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03338712 | Micro-RNA Expression Profiles in Localised Prostate Cancer | withdrawn | — | 0 | Wuerzburg University HospitalOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT00548730 | Comparison Trial of White Light, Autofluorescence and Narrow Band Imaging Bronchoscopy(NWA) | withdrawn | — | 0 | Antonios LikourezosOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | withdrawn | N/A | 0 | Qure Healthcare, LLCINDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06159998 | New Markers for Treatment Response to Radiotherapy in Prostate Cancer | withdrawn | — | 0 | University of BaselOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02017366 | Design of the EFECTS Trial(EFECTS) | withdrawn | N/A | 0 | University Hospital, GasthuisbergOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections | withdrawn | Phase 3 | 0 | Antonios LikourezosOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Juan C. Ramos, MDOTHER | 0 | Dec 4, 2023 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT05791474 | ATI-2231 in Advanced Solid Tumor Malignancies | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT00657332 | Clinical and Pathologic Studies in Neuroendocrine Tumors | withdrawn | — | 0 | Stanford UniversityOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)(PANORAMA2) | withdrawn | N/A | 0 | Techsomed Medical Technologies LTDINDUSTRY | 0 | Nov 27, 2023 | clinicaltrials |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 2, 2024source: clinicaltrials